Recalled Medicines & supplements – Current GIS Alerts 2026
Found 698 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Corsib
Unidentified degradation impurities of the active substance pose a real and direct threat to patients; due to their unconfirmed nature, a risk to the patient’s health and life cannot be excluded. Potential effects: severe adverse reactions, complications, life‑threatening events.
Corsib
Due to the unconfirmed nature of degradative impurities of the active substance, a risk to the patient’s health and life cannot be excluded; the unidentified impurities pose a real and direct threat to patients using the product. Potential effects: poisoning, unpredictable adverse reactions, lack of efficacy in treating heart disease and hypertension.
Clotidal MAX
Negative test result for the appearance parameter – damaged, chipped tablet edges and detached fragments, probably due to too low water content in the granulate and lower hardness, which may affect dose integrity and comfort of use. Potential effects: reduced treatment efficacy or irritation.
Trazodone Neuraxpharm
An out-of-specification (OOS) result was recorded for the tablet hardness parameter, potentially linked to different blister foils and gas permeability, which could affect product hardness during storage. Potential effects: possible changes in active substance release, altered bioavailability and efficacy, although the investigation showed no significant impact.
Underground Super Lemon dietary supplement (lemon-pineapple flavor)
High content of Δ9-THC in the dietary supplement. Potential effects: poisoning, psychological disturbances and health risks.
APAP dla dzieci FORTE
The suspension contains gas bubbles, is foamy and completely or almost completely fills the bottle, preventing shaking, homogenization and correct dosing of the medicinal product. Potential effects: improper dosing of paracetamol, lack of efficacy or overdose, possible adverse reactions.
APAP dla dzieci FORTE
The suspension in the bottles contained gas bubbles, was foamed, non-homogeneous and layered, and the bottles were completely or almost completely filled, which prevented shaking, homogenization and correct dosing of the medicinal product. Potential effects: incorrect paracetamol dose, lack of treatment efficacy or risk of overdose.
Tadalafil Aurovitas
The batch TGSD21011-A did not meet quality requirements due to a negative result for the parameter “release of tadalafil within 15 minutes”, which may affect treatment effectiveness. Potential effects: lack of therapeutic efficacy.
Auroverin MR
The test showed that the release of mebeverine hydrochloride was slower than allowed by quality requirements, which affects the product’s effectiveness and poses a real and direct threat to patients’ health or life. Potential effects: lack of treatment efficacy, possible worsening of symptoms, complications.
Syldenafilu cytrynian
If the description of the primary packaging of the pharmaceutical substance does not match its actual content, there is a risk of using the wrong substance in compounding a prescription medicine. An incorrect expiry date may lead to use beyond the period with guaranteed efficacy and safety. Potential effects: lack of treatment efficacy, adverse reactions, complications.
Syldenafilu cytrynian
It was found that packaging may be incorrectly labelled, including substance name, batch number and expiry date, which can lead to using the wrong raw material in compounded medicines or using it after the period guaranteeing its efficacy and safety. Potential effects: lack of treatment efficacy, adverse reactions or complications due to use of an incorrect active substance.
Autostrzykawka Morfina Przeciwko Bólowi
A problem with solution color was identified: in 4 of 92 auto-injectors the liquid was light green or green instead of colorless or pale yellow, linked to a decrease in the excipient sodium metabisulfite in batch 151021A. Potential effects: possible reduced efficacy and safety of treatment, unpredictable drug action.
Oxylaxon
A quality defect was identified involving excessively high oxycodone hydrochloride content in certain Oxylaxon prolonged-release tablet batches, caused by abnormal parameters of granulate batch EE03807. Potential effects: opioid overdose, respiratory depression, poisoning.
Oxylaxon
Failure of the medicinal products to meet the specified quality requirement manifests as excessively high content of one of the two active substances, oxycodone hydrochloride, which may expose patients to receiving a substandard medicinal product. Potential effects: excessive opioid effect, serious adverse reactions, complications of pain therapy.
Oxylaxon
The failure of the medicinal products to meet the established quality requirement manifests as an excessively high content of one of the two active substances, i.e. oxycodone hydrochloride. Potential effects: risk of overdose, poisoning, and increased opioid adverse effects.
Oxylaxon
A quality defect was identified consisting of an excessively high content of oxycodone hydrochloride in selected product batches, resulting from the use of granulate with incorrect quality parameters. Potential effects: opioid overdose, increased adverse reactions, respiratory depression, serious health complications.
Oxylaxon
In this case, the failure of the medicinal products to meet their specified quality requirement manifests as an excessively high content of one of the two active substances, i.e. oxycodone hydrochloride. Potential effects: opioid overdose, increased adverse reactions, risk to the patient’s health.
Oxylaxon
In this case, the failure of the medicinal products to meet their established quality requirement manifests as an excessively high content of one of the two active substances, i.e. oxycodone hydrochloride. Potential effects: risk of opioid overdose, increased adverse reactions, respiratory complications.
Linezolid Polpharma
Incorrect release of the active substance from the medicinal product, to an extent that may affect its therapeutic properties, constitutes a real risk to patients' health due to the potential lack of efficacy. Potential effects: ineffective treatment of infections, risk of disease progression or complications.
Benodil
The quality defect consists in labelling Benodil 0.25 mg/ml ampoules with Budixon Neb 0.5 mg/ml labels, which may mislead regarding the dose and use of the medicine. Potential effects: incorrect dosing, lack of therapeutic efficacy, or risk of complications in patients requiring an accurate corticosteroid dose.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.